Literature DB >> 21861836

Endothelial progenitor cells in prehypertension.

Rossella Di Stefano1, Maria Chiara Barsotti, Francesca Felice, Charalambos Vlachopoulos, Alberto Balbarini.   

Abstract

Blood pressure within prehypertensive levels confers higher cardiovascular risk. As prehypertension is also an intermediate stage for full hypertension, a precocious intervention with lifestyle changes or drugs is therefore appealing. Endothelial injury and dysfunction are thought to contribute to cardiovascular risk in prehypertension. Endothelial progenitor cell impairment has been linked to endothelial dysfunction, atherosclerotic disease progression and cardiovascular events. A potential mechanism contributing to the heightened cardiovascular risk in prehypertension may be linked to abnormalities in endothelial progenitor cell number and/or function. Aim of this review is to be up to date about the recent work on the correlation between endothelial progenitor cells and prehypertension and the possible prevention, treatment, and control of this pathology. The effect of an approach based on dietary intervention on both blood pressure and endothelial progenitor cells will be also shown.

Entities:  

Mesh:

Year:  2011        PMID: 21861836     DOI: 10.2174/138161211798157775

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Berberine-Promoted CXCR4 Expression Accelerates Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Persons with Prehypertension.

Authors:  Yi-Jia Shao; Jun Tao; Bing-Bo Yu; Dan Meng; Xu-Long Yang; Jia-Pan Sun; Yan-Xia Qiu; Xiao-Yu Zhang
Journal:  Chin J Integr Med       Date:  2018-10-19       Impact factor: 1.978

2.  Increased endothelial progenitor cells and nitric oxide in young prehypertensive women.

Authors:  Yang Zhen; Songhua Xiao; Zi Ren; Hong-Wei Shen; Huanxing Su; Yong-Bo Tang; Haitao Zeng
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-02-16       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.